JP6566867B2 - 生きている患者でのアルツハイマー病アッセイ - Google Patents

生きている患者でのアルツハイマー病アッセイ Download PDF

Info

Publication number
JP6566867B2
JP6566867B2 JP2015521863A JP2015521863A JP6566867B2 JP 6566867 B2 JP6566867 B2 JP 6566867B2 JP 2015521863 A JP2015521863 A JP 2015521863A JP 2015521863 A JP2015521863 A JP 2015521863A JP 6566867 B2 JP6566867 B2 JP 6566867B2
Authority
JP
Japan
Prior art keywords
hydrocarbyl
flna
ring
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015521863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529802A5 (https=
JP2015529802A (ja
Inventor
ホアウ−ヤン ワン
ホアウ−ヤン ワン
バルビエ リンジー バーンズ
バルビエ リンジー バーンズ
Original Assignee
ペイン セラピューティクス インコーポレイテッド
ペイン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ペイン セラピューティクス インコーポレイテッド, ペイン セラピューティクス インコーポレイテッド filed Critical ペイン セラピューティクス インコーポレイテッド
Publication of JP2015529802A publication Critical patent/JP2015529802A/ja
Publication of JP2015529802A5 publication Critical patent/JP2015529802A5/ja
Application granted granted Critical
Publication of JP6566867B2 publication Critical patent/JP6566867B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2015521863A 2012-07-13 2013-07-12 生きている患者でのアルツハイマー病アッセイ Active JP6566867B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261671445P 2012-07-13 2012-07-13
US61/671,445 2012-07-13
US201361789180P 2013-03-15 2013-03-15
US61/789,180 2013-03-15
PCT/US2013/050368 WO2014012054A1 (en) 2012-07-13 2013-07-12 Alzheimer's disease assay in a living patent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019139317A Division JP6796168B2 (ja) 2012-07-13 2019-07-30 生きている患者でのアルツハイマー病アッセイ

Publications (3)

Publication Number Publication Date
JP2015529802A JP2015529802A (ja) 2015-10-08
JP2015529802A5 JP2015529802A5 (https=) 2016-09-01
JP6566867B2 true JP6566867B2 (ja) 2019-08-28

Family

ID=49914282

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015521863A Active JP6566867B2 (ja) 2012-07-13 2013-07-12 生きている患者でのアルツハイマー病アッセイ
JP2019139317A Active JP6796168B2 (ja) 2012-07-13 2019-07-30 生きている患者でのアルツハイマー病アッセイ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019139317A Active JP6796168B2 (ja) 2012-07-13 2019-07-30 生きている患者でのアルツハイマー病アッセイ

Country Status (4)

Country Link
US (4) US9354223B2 (https=)
EP (1) EP2872899B1 (https=)
JP (2) JP6566867B2 (https=)
WO (1) WO2014012054A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6566867B2 (ja) 2012-07-13 2019-08-28 ペイン セラピューティクス インコーポレイテッド 生きている患者でのアルツハイマー病アッセイ
CA2894157A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
UA118548C2 (uk) 2012-12-21 2019-02-11 Епізайм, Інк. Тетрагідро- та дигідроізохіноліни як інгібітори prmt5 та їх застосування
JP2016505000A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
EP3406607A1 (en) 2012-12-21 2018-11-28 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
US9611257B2 (en) 2012-12-21 2017-04-04 Epizyme, Inc. PRMT5 inhibitors and uses thereof
EP3177288A4 (en) 2014-08-04 2018-04-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP6463162B2 (ja) * 2015-02-10 2019-01-30 キヤノン株式会社 記録制御装置、記録制御方法、及びプログラム
WO2016207845A1 (en) * 2015-06-26 2016-12-29 Bisio Progetti S.P.A. Single-dose capsule for the preparation of beverages
TN2017000544A1 (en) 2015-07-31 2019-04-12 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
MA44037B1 (fr) 2016-06-06 2020-03-31 Arena Pharm Inc Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
US11040935B2 (en) 2016-10-05 2021-06-22 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule AMPK activators
RU2720203C1 (ru) 2017-01-20 2020-04-27 Пфайзер Инк. 1,1,1-трифтор-3-гидроксипропан-2-илкарбаматные производные как ингибиторы magl
CN110198944A (zh) 2017-01-23 2019-09-03 辉瑞大药厂 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物
CA3185336A1 (en) * 2017-11-06 2019-05-09 Acelot, Inc. Small molecule drugs and related methods for treatment of diseases related to a.beta.42 oligomer formation
US12186307B2 (en) 2019-02-13 2025-01-07 Yale University Methods of treating epilepsy
CA3131146A1 (en) 2019-02-21 2020-08-27 Pain Therapeutics, Inc. Solid polymorphs of a flna-binding compound and its hydrochloride salts
EP3934647A1 (en) * 2019-03-06 2022-01-12 LDN Pharma Limited Method for determining efficacy
EP4027987A4 (en) 2019-09-10 2023-11-29 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods and materials for increasing level of phosphorylated ampk protein
WO2022098700A1 (en) * 2020-11-03 2022-05-12 Cassava Sciences, Inc. Inhibiting an immune response mediated by one or more of tlr2, rage, ccr5, cxcr4 and cd4
JP2024527899A (ja) * 2021-07-23 2024-07-26 キャッサバ サイエンシズ インコーポレイテッド 生きている被験者におけるアルツハイマー病の成分アッセイ

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1220440B (de) 1962-02-14 1966-07-07 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von Derivaten des 1-(o-Bromphenoxy)-2-hydroxy-3-amino-propans und deren Saeureadditionssalzen
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
ES2306482T3 (es) * 1997-08-28 2008-11-01 Novartis Ag Antagonistas de antigeno-1 funcion con funcion de linfocito.
EP1083889B1 (en) * 1998-06-01 2003-12-10 Ortho-McNeil Pharmaceutical, Inc. Tetrahydronaphtalene compounds and their use for the treatment of neurodegenerative diseases
EP1233979A1 (en) * 1999-12-01 2002-08-28 Ortho-McNeil Pharmaceutical, Inc. Method of diagnosing neurodegenerative disease
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
US20050075505A1 (en) 2002-01-14 2005-04-07 Gandhi Biren Jaiprakash Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone
BR0309875A (pt) 2002-05-03 2007-04-10 Israel Inst For Biolog Res Isr métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto
US20070149543A1 (en) 2003-01-29 2007-06-28 Stockwell Brent R Agents For Treating Neurodegenerative Diseases
DE102004014296A1 (de) 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8-Triazaspiro[4.5]decan-2-on-Verbindingen
DE102004014304A1 (de) 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
CA2626005A1 (en) 2005-10-13 2007-10-25 Waratah Pharmaceuticals Inc. Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
FR2905009A1 (fr) * 2006-08-18 2008-02-22 Servier Lab Methode de criblage de composes aux proprietes anti-amyloide
US8653068B2 (en) 2009-10-30 2014-02-18 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US8614324B2 (en) 2008-10-31 2013-12-24 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US8722851B2 (en) 2007-11-02 2014-05-13 Pain Therapeutics, Inc. Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A
CL2008003507A1 (es) * 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US20100279997A1 (en) 2009-05-04 2010-11-04 Lindsay Burns Barbier Analgesic that binds filamin a
US8580808B2 (en) 2009-10-30 2013-11-12 Pain Therapeutic, Inc. Filamin A-binding anti-inflammatory analgesic
US20100279996A1 (en) 2009-05-04 2010-11-04 Lindsay Burns Barbier Novel analgesic that binds filamin a
WO2010088400A1 (en) 2009-01-28 2010-08-05 Catholic Healthcare West Methods of diagnosing and treating neurodegenerative diseases
US20100280061A1 (en) 2009-05-04 2010-11-04 Lindsay Burns Barbier Novel analgesic that binds filamin a
US8580809B2 (en) 2009-10-30 2013-11-12 Pain Therapeutics, Inc. Filamin A-binding anti-inflammatory analgesic
ES2716049T3 (es) * 2012-07-13 2019-06-07 Pain Therapeutics Inc Un método para inhibir la fosforilación de tau
JP6566867B2 (ja) 2012-07-13 2019-08-28 ペイン セラピューティクス インコーポレイテッド 生きている患者でのアルツハイマー病アッセイ

Also Published As

Publication number Publication date
JP2019206558A (ja) 2019-12-05
US11385221B2 (en) 2022-07-12
US9500640B2 (en) 2016-11-22
EP2872899A1 (en) 2015-05-20
EP2872899A4 (en) 2015-12-30
EP2872899B1 (en) 2018-07-11
US9354223B2 (en) 2016-05-31
US10222368B2 (en) 2019-03-05
US20160266149A1 (en) 2016-09-15
US20190271686A1 (en) 2019-09-05
JP6796168B2 (ja) 2020-12-02
WO2014012054A1 (en) 2014-01-16
US20140017699A1 (en) 2014-01-16
US20140017698A1 (en) 2014-01-16
JP2015529802A (ja) 2015-10-08

Similar Documents

Publication Publication Date Title
JP6566867B2 (ja) 生きている患者でのアルツハイマー病アッセイ
US20210389298A1 (en) Alzheimer's Disease Assay in a Living Patient
JP2010502751A (ja) キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
JP2002539260A (ja) アスパルチルプロテアーゼインヒビターを使用して神経変性障害を処置する方法
EP2438444A1 (en) Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
JP6639512B2 (ja) 診断方法、治療剤およびその使用
US20210121565A1 (en) Combination Therapy
US20070202547A1 (en) Methods For Detecting Substances Which Bind To The Amyloid Precursor Protein Or Beta Amyloid Fragments, And Binding Compounds
US20240336620A1 (en) Protein degradation compounds and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160712

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190703

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190730

R150 Certificate of patent or registration of utility model

Ref document number: 6566867

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250